According to the results of two pioneering PD-1 applications in HCC patients, nivolumab and pembrolizumab both showed an unsatisfactory DCR of 64% and 62%, respectively (13, 14), meaning that nearly 30–40% patients failed to respond to anti-tumor therapy (also means progressive disease, PD). This evidence concerns the gene PDCD1 and neoplasm.